Home
This site is intended for healthcare professionals

The Evolving CIDP Paradigm in Clinical Practice

3rd Dec 2026
12:30 - 1:30am (GMT)
3rd Dec 2026
12:30 - 1:30am (GMT)
Hosted on MedAll
Attendance certificate available
Free
Online

Description

This activity is supported by an independent education grant from Argenx. This online education program has been designed solely for healthcare professionals in the USA. The information is this program is not suitable for any other country.

Navigating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) remains a complex clinical challenge, with up to 50% of community diagnoses misclassified and many patients silently deteriorating between treatment cycles. Join leading experts Prof. Sami Khella, Prof. Chafic Karam, and Prof. Karissa Gable for this accredited virtual webinar, designed to translate the latest evidence into routine neurological practice.

This accredited CME activity directly addresses critical practice gaps—equipping clinicians to master the stringent 2021 EAN/PNS diagnostic criteria, differentiate challenging mimics and distinct autoimmune nodopathies, implement validated objective monitoring tools (such as grip dynamometry and I-RODS), and adopt proactive management strategies that preempt irreversible axonal loss and long-term disability.

Session Highlights

  • Apply Updated Diagnostic Guidelines: Accurately implement the 2021 EAN/PNS clinical and electrodiagnostic criteria, correctly interpreting nerve conduction studies alongside supportive modalities (such as CSF analysis and high-resolution nerve ultrasound) to secure timely, definitive diagnoses.
  • Differentiate Mimics and Distinct Variants: Distinguish typical CIDP from clinical variants (e.g., multifocal, distal, motor, sensory) and clinical mimics—including POEMS syndrome and independently classified autoimmune nodopathies—to prevent diagnostic error and ensure appropriate therapy selection.
  • Integrate Validated Objective Clinimetrics: Incorporate standardized measurement instruments, including the I-RODS centile scale, the INCAT disability scale, and quantitative grip strength dynamometry, into everyday practice rather than relying on subjective clinical impressions.
  • Detect Subtle Treatment Fluctuations: Identify end-of-cycle wear-off and treatment-related fluctuations (TRFs) in patients receiving maintenance therapy, uncovering hidden functional deterioration to enable timely, evidence-based treatment optimization.
  • Implement Proactive Disease Trajectory Monitoring: Formulate structured, longitudinal monitoring protocols guided by the natural history of CIDP to distinguish active inflammatory disease from chronic axonal damage, intervening early to prevent permanent disability.

Who Should Watch

This program is designed for:

  • Neurologists and Pediatric neurologists
  • Neuromuscular Specialists
  • Advanced practice providers (Physician Assistants, Nurse Practitioners)

Faculty

Sami Khella, MD, is Professor and former Chief of The Department of Neurology at the University of Pennsylvania. Born in Egypt, down the street from the pyramids, he graduated from the University of Pennsylvania School of Medicine. Before medical school, he studied biology and fine arts at Penn. His career has been mostly at Penn, though he lived in France for a few years. Over 20 years ago, he founded the Penn Presbyterian Myasthenia Gravis Center, which has grown into one of the biggest myasthenia programs in the US. Dr. Khella has been involved in many pivotal clinical trials. He runs several centers of excellence for myasthenia gravis, amyloid neuropathy and CIDP. He is the author or co-author of many papers detailing this disease as well as other neuromuscular disorders, such as, amyloid neuropathy and chronic inflammatory demyelinating polyneuropathy (CIDP).

Chafic Karam, MD, is Professor of Neurology and Chief of the Neuromuscular Division at the University of Pennsylvania. He earned his medical degree from Saint Joseph's University in Beirut, completed his neurology residency at Mount Sinai Beth Israel, and completed fellowships in neuromuscular disorders at Mass General Brigham and peripheral nerve pathology at the Mayo Clinic. Dr. Karam holds board certifications in neurology, neuromuscular medicine, and muscle and nerve pathology. A prolific clinical researcher with more than 150 publications and 50 clinical trials, his clinical research focuses on neuropathy, with a particular emphasis on conditions related to amyloidosis and autoimmune disorders, including GBS, CIDP, MMN, and vasculitic neuropathies. He also serves on several prominent journal editorial boards and advises the GBS/CIDP Global Medical Advisory Board. He is committed to the training and mentorship of the next generation of neuromuscular specialists.

Karissa L. Gable, MD, FAAN, is a Professor in the Department of Neurology at Duke University Medical Center in Durham, North Carolina, where she is also the Neuromuscular Medicine Fellowship Director and the Director of the Neurology medical student clerkship for the School of Medicine. She received her medical degree from the University of North Carolina-Chapel Hill School of Medicine. She completed a residency in Adult Neurology at Northwestern Memorial Hospital in Chicago and a fellowship in Neuromuscular Medicine at Harvard Medical School–Massachusetts General Hospital/Brigham and Women's Hospital in Boston. She is a diplomate in Neurology, Electrodiagnostic Medicine, and Neuromuscular Medicine. Dr. Gable’s area of research interest is autoimmune neuromuscular disease, including neuromuscular junction disease and autoimmune neuropathies.

Disclosures

Sami Khella, MD - TBC

Chafic Karam, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board, Consultant, and Speaker for Acceleron, Alpine, Alexion, Alnylam, Amgen, Amicus, Annexon, Applied Therapeutics, Argenx, Astra Zeneca, Biogen, Catalyst, Corino, CSL Behring, Dianthus, Genentech, GenSci, Griffols, ImmunAbs, Immunovant, Intellia, Ionis, J&J, Kyverna, Medison, Neuroderm, Novo Nordisk, Nuvig, Octapharma, Pfizer, Sanofi, UCB, Takeda, Vertex, and Zai Lab. Chafic Karam, MD, will disclose any unlabeled/unapproved uses of drugs or products referenced during the presentation/materials.

Karissa Gable, MD, FAAN, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board, Consultant, and Speaker for Annexon, Argenx, CSL Behring, Dianthus, Grifols, Immunovant, Sanofi, and Takeda. Karissa Gable, MD, FAAN, will disclose any unlabeled/unapproved uses of drugs or products referenced during the presentation/materials.

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 ANCC contact hours.

Fee Information

There is no fee for this educational activity.

Learning objectives

  1. Apply the 2021 EAN/PNS clinical and electrodiagnostic criteria, alongside supportive modalities such as high-resolution nerve ultrasound and CSF analysis, to achieve timely and accurate diagnosis of CIDP and support appropriate patient management.
  2. Differentiate clinical mimics of CIDP from classical CIDP spectrum disorders to reduce misclassification and support accurate diagnosis and appropriate management.
  3. Integrate validated, objective monitoring instruments—such as the I-RODS centile score, the INCAT disability scale, and quantitative grip strength dynamometry—into routine clinical assessments to accurately capture insidious treatment-related fluctuations (TRFs) and end-of-cycle wear-off.
  4. Implement proactive monitoring strategies informed by the natural history of CIDP and symptoms of suboptimally managed disease.
View all

Similar events and on demand videos

 
3rd Dec 2026
12:30 - 1:30am (GMT)
Hosted on MedAll
Attendance certificate available
Free
Online